Close

Dr. Jeremy Levin (Ovid Therapeutics) at the 2017 BIO International Convention

Mike Huckman interviews Dr. Jeremy Levin (Ovid Therapeutics) at the 2017 BIO International Convention Buzz Center.

Nima Farzan (PaxVax) at the 2017 BIO International Convention

Mike Huckman interviews Nima Farzan (PaxVax) at the 2017 BIO International Convention Buzz Center.

Khyati Roberts (Abbvie) at the 2017 BIO International Convention

Mike Huckman interviews Khyati Roberts (Abbvie) at the 2017 BIO International Convention Buzz Center.

T.J. Sharpe at the 2017 BIO International Convention

Mike Huckman interviews T.J. Sharpe at the 2017 BIO International Convention Buzz Center.

Jay P. Siegel, MD (Johnson & Johnson) at the 2017 BIO International Convention

Mike Huckman interviews Jay P. Siegel, MD (Johnson & Johnson) at the 2017 BIO International Convention Buzz Center.

Rowan Chapman (Johnson & Johnson) at the 2017 BIO International Convention

Mike Huckman interviews Rowan Chapman (Johnson & Johnson) at the 2017 BIO International Convention Buzz Center.

Daniel Skovronsky (Eli Lilly and Company) at the 2017 BIO International Convention

Mike Huckman interviews Daniel Skovronsky (Eli Lilly and Company) at the 2017 BIO International Convention Buzz Center.

Steve Isaacs (Aduro Biotech) at the 2017 BIO International Convention

Mike Huckman interviews Steve Isaacs (Aduro Biotech) at the BIO 2017 Buzz Center.

BIO Applauds House Passage of Food and Drug Administration Reauthorization Act (FDARA)

Urges swift Senate vote to ensure continuity of critical FDA functions   Washington, DC (July 12, 2017) – Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement today regarding passage of the Food and Drug Administration Reauthorization Act (FDARA) by the U.S. House of Representatives:

Endpoints: BIO Comments on FDA Multiple Endpoints in Clinical Trials

The Biotechnology Innovation Organization (BIO) thanks the Food and Drug Administration (FDA) for the opportunity to submit comments on the Draft Guidance “Multiple Endpoints in Clinical Trials” (Draft Guidance).